# Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

> **NCT02855359** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 24 (actual)

## Conditions studied

- Diffuse, Large B-Cell, Lymphoma
- Follicular Lymphoma, Grade 3b
- Transformed Lymphoma / DLBCL

## Interventions

- **DRUG:** denintuzumab mafodotin
- **DRUG:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** vincristine
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT02855359
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08
- **Primary completion:** 2018-01
- **Final completion:** 2018-05-15
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855359, "Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02855359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*